Who else can act on what a peptide website claims? The FTC can, it asks for evidence, not approval, and after one Supreme Court case its money runs through a public list of 672 companies with no peptide seller on it
Reference page · published 2026-10-18
Disclosure: this index is operated by Artemis Labs, which sells research compounds to laboratories. Artemis Labs is not named on the list described below, has no connection to any company named on this page, and does not sell any of the product types the documents quoted here were addressed to. Nothing here is legal advice and nothing here states whether any particular company, claim or advertisement does or does not violate anything. Every quotation on this page is verbatim from a federal statute, a federal regulation, a Federal Register notice, a published opinion of the Supreme Court of the United States, or a document published by the Federal Trade Commission — each of which was fetched and read for this page on October 18, 2026, and each of which is listed under Sources with the byte count of the response. This page deliberately names no compound. It is about a mechanism that does not depend on which molecule is in the vial, and keeping compounds out of it is the point and not an omission.
Short answer: the FTC, and the thing to understand is that it asks a different question than FDA does. FDA asks whether something is being sold as a drug without approval. The FTC asks whether an advertising claim is supported, and the support it requires for a health claim is
competent and reliable scientific evidence. Its own guidance says in terms that animal and laboratory-dish studiesmay provide useful supporting or background information, but, without confirmation by human RCTs, they aren’t sufficient to substantiate health-related claims. That sentence is the whole relationship between this agency and a research-compound website, because the literature those websites cite is mostly animal and laboratory-dish work. The second thing to understand is about money. In April 2021 the Supreme Court took away the route the FTC had been using to collect it. The agency’s workaround was to publish a list of companies it had formally notified, because the penalty statute only reaches someone withactual knowledge. We counted 672 names on that list. The word peptide appears in none of them.
This index holds 109 pages about enforcement in this category, and nearly all of them are about one agency. Measured against those pages on October 18, 2026, the word substantiation appears zero times. So do deceptive advertising, Health Products Compliance, civil penalty, attorney general and class action. The full name Federal Trade Commission appears on exactly one page. The abbreviation FTC appears on five, and 18 of its 30 occurrences are on a single page about one letter the two agencies signed together in 2020. Live controls on the same files, counted the same way: warning letter 758 occurrences across 85 pages, misbranded 136 across 27, research use only 56 across 21, and a deliberately nonsense control string at zero. The zeros above are readings, not an absence of looking.
One method note belongs with those numbers, because it is the kind of thing that turns a measurement into a mistake. The same probe reported Section 5 on 24 pages, which looked like coverage of the FTC Act’s operative section. It is not. It is a substring match inside Section 502 and similar citations to the food and drug statute. The counts above are substring counts with controls, and the one string where a substring could mislead is named here and is not reported as a finding.
Two agencies, one letter, two different questions
The cleanest demonstration that these are separate questions is a document where both were asked at once. On December 7, 2020, FDA and the FTC jointly signed a warning letter to a research-compound seller about a single blog post. We hold a full record of that letter, and the reason it is worth returning to is the structure, not the subject. FDA’s half asks about approval. The FTC’s half asks about evidence, and it states its own rule in one sentence:
In addition, it is unlawful under the FTC Act, 15 U.S.C. 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made.
Read the conditional. It does not ask whether the product works. It asks what the advertiser possessed, and when. A claim can turn out to be true and still have been unlawful when it was made, because the thing being regulated is the basis for saying it. That is a different proposition from anything in a warning letter about unapproved drug status, and the two sit in the same envelope.
The letter also tells the recipient what the consequence is, and this sentence is the reason the rest of this page exists:
Violations of the FTC Act may result in legal action seeking a Federal District Court injunction and an order may require that you pay back money to consumers.
That was accurate on the day it was written. One hundred and thirty-six days later the Supreme Court held that the statute the FTC had been using for that money does not authorize it.
What the FTC actually asks for
The FTC’s staff guidance for this whole area is a 42-page document called
Health Products Compliance Guidance, published in December 2022. Its first substantive
paragraph says what it is: guidance that will update and replace Dietary Supplements: An
Advertising Guide for Industry, issued in 1998
. It also says how broadly it reads the word
advertising — traditional TV, radio, print, and internet ads
and also
the variety of marketing techniques and promotion methods that marketers engage in
. A website
is advertising. So is the material around a product.
The standard it applies has two parts, quoted here from the guidance itself. The evidence must be
of a kind generally accepted in the profession to yield accurate and reliable results
, and
separately it must be
sufficient in quality and quantity based on standards generally accepted in the relevant scientific fields, when considered in light of the entire body of relevant and reliable scientific evidence, to substantiate that the representation is true.
The phrase the entire body
is doing real work there. An advertiser cannot select the
favorable studies and satisfy this standard with them; the standard is applied to the literature as
a whole, including the parts that point the other way. On what that body generally has to contain,
the guidance is blunt:
As a general matter, substantiation of health-related benefits will need to be in the form of randomized, controlled human clinical testing to meet the competent and reliable scientific standard.
Where this lands on a page full of citations
Here is the sentence that matters most to anyone who reads or writes research-compound content, and it is a direct quotation from the same guidance:
Animal and in vitro studies may provide useful supporting or background information, but, without confirmation by human RCTs, they aren’t sufficient to substantiate health-related claims.Animal studies have only limited value in predicting the effect of a product in humans, making it difficult to extrapolate results in animal research to benefits for humans.On laboratory-dish work: itmay help identify a possible mechanism of action, but similarly are of limited value to predict benefits for humans.
Almost the entire published literature on research compounds is animal and in vitro work. Under the FTC’s standard, that literature is background. It is not nothing — the guidance says it may provide useful supporting information, and a mechanism found in a dish is a real scientific finding. But it cannot carry a claim about what a product does for a person. There is no quantity of it that adds up to substantiation, because the deficiency is in the kind of evidence, not the amount.
The consequence for a vendor is not subtle. A page can be built entirely out of real, correctly cited, peer-reviewed papers and still be making an unsupported claim, if the claim it makes is about a human benefit and the papers are about rodents. The citations do not fix the claim. The only thing that fixes it is not making the claim.
Two of the guidance’s own worked examples show the failure mode precisely, and both are
about the description of the evidence, not the product. In Example 17 an advertiser
claims its product is based on Nobel Prize-Winning
research and has been proven
effective
by $5 Million in NIH Research
, when the prize concerned an unrelated use of the
active ingredient and the federally funded work examined the safety, but not the efficacy, of the
active ingredient
. The conclusion the guidance draws is the part to sit with:
The specific claims about the level of support are deceptive even if the advertiser possesses other research that provides competent and reliable scientific evidence of efficacy.
In other words, being right about the product is not a defense to being wrong about your
evidence. Example 19 is the same error in the animal literature: a claim resting on animal research
uses a species of animal that, unlike humans, is able to synthesize the vitamin
and on an
in vitro study using a different formulation with a higher concentration of the compound than the
product being marketed
. Real studies. Wrong species, wrong preparation, wrong question.
And in a footnote on its last page, the guidance records a position that applies directly to a page like this one. Citing the papers is itself part of the claim:
citation to clinical studies can contribute to a clinically proven claim
One more example is worth quoting because it is about design, not words. Example 1
describes a brochure showing images of doctors in white lab coats looking through microscopes,
molecular structures, and a stack of medical journals
, and concludes that these
give an impression of scientific legitimacy and likely convey an implied claim that the product
has been clinically proven to be effective
. Molecular structures and journal references are the
standard visual vocabulary of this category, including on pages like
ours about analytical methods. The guidance’s point
is that an implied claim is a claim.
What happened to the money: April 22, 2021
The FTC had, for decades, gone straight to a federal district court under Section 13(b) of its own Act and asked for money — restitution and disgorgement — alongside an injunction. In AMG Capital Management, LLC v. FTC, No. 19-508, argued January 13, 2021 and decided April 22, 2021, the Supreme Court ended that. The case itself was about deceptive payday lending, and the district court had ordered the defendant to pay $1.27 billion. The holding, quoted from the opinion:
Section 13(b) does not authorize the Commission to seek, or a court to award, equitable monetary relief such as restitution or disgorgement.
The reasoning is textual and structural. Section 13(b) says the Commission may seek . . . a
permanent injunction
, and
By its terms, this provision concerns prospective injunctive relief, not retrospective monetary relief.
The Court also pointed at a different section as proof that Congress knew how to authorize money
when it wanted to, describing the conditioned and limited monetary relief
authorized in
Section 19. That section is 15 U.S.C. § 57b, and reading it shows what
conditioned means. After a cease and desist order becomes final, the FTC can sue for
consumer redress, but only if
the Commission satisfies the court that the act or practice to which the cease and desist order relates is one which a reasonable man would have known under the circumstances was dishonest or fraudulent
A dispute about whether a company’s studies were good enough is not obviously a dispute about something a reasonable person would have known was dishonest or fraudulent. That gap is what the next section is a response to.
The list that puts the money back
There is a second money route in the FTC Act, and it has existed all along: civil penalties under Section 5(m)(1)(B), 15 U.S.C. § 45(m)(1)(B). Quoted from the statute, the Commission may seek a penalty against anyone who engages in a practice
(1) after such cease and desist order becomes final (whether or not such person, partnership, or corporation was subject to such cease and desist order), and (2) with actual knowledge that such act or practice is unfair or deceptive and is unlawful under subsection (a)(1) of this section.
Read the parenthetical in clause (1), because it is the hinge of the whole mechanism. The order does not have to have been against you. Someone else’s final order, in some earlier case, can supply the rule. What clause (2) then requires is that you knew about it.
So the FTC’s problem after April 2021 was an evidentiary one: how do you establish that a
company had actual knowledge
? The answer was to tell them, in writing, and keep the receipt.
The Commission voted on March 31, 2023 to issue a Notice of Penalty Offenses Concerning
Substantiation of Product Claims, and the notice is dated April 13, 2023 — thirteen days
later. It is a two-page document listing five practices the Commission has already determined are
unlawful. All five, verbatim, because the wording is the substance:
It is an unfair or deceptive act or practice for an advertiser to make an objective product claim without having a reasonable basis, at the time the claim is made, consisting of competent and reliable evidence.
It is an unfair or deceptive act or practice for an advertiser to make a claim relating to the health benefits or safety features of a product without possessing and relying upon competent and reliable scientific evidence that has been conducted and evaluated in an objective manner by qualified persons and that is generally accepted in the profession to yield accurate and reliable results, to substantiate that the claim is true.
It is an unfair or deceptive act or practice for an advertiser to represent expressly or by implication that a product is effective in the cure, mitigation, or treatment of any serious disease, including heart disease, cancer, arthritis, and erectile dysfunction, without possessing and relying upon at least one human clinical trial of the product that (1) is randomized, (2) is well controlled, (3) is double-blinded (unless the marketer can demonstrate that blinding cannot be effectively implemented given the nature of the intervention), (4) is conducted by persons qualified by training and experience to conduct such studies, (5) measures disease end points or validated surrogate markers, and (6) yields statistically significant results.
It is an unfair or deceptive act or practice for an advertiser to misrepresent the level or type of substantiation for a claim.
It is an unfair or deceptive act or practice to represent that a product claim has been scientifically or clinically proven unless, at the time the representation is disseminated, the advertiser possesses and relies upon evidence sufficient to satisfy the relevant scientific community of the claim’s truth.
Items 4 and 5 are the two that a citation-dense page can fail without printing a single false study. Neither is about whether a compound does anything. Both are about how an advertiser characterizes its own evidence. Every one of the five carries footnotes to the litigated Commission decisions that establish it — POM Wonderful, Daniel Chapter One, Thompson Medical, ECM Biofilms, Removatron, Bristol-Myers, Cliffdale Associates and others — because under the statute it is a final order that makes a practice a penalty offense, not the notice.
The FTC then published who it had sent the notice to. The list is a 16-page PDF headed
List of April 2023 Recipients of the FTC’s Notice of Penalty Offenses Concerning
Substantiation of Product Claims
, updated May 11, 2023
, and it carries a line of its own
in the header of every page:
The fact that a company is on this list is NOT an indication that it has done anything wrong
That disclaimer is worth holding next to the other public federal list this index describes. On an FDA import alert, appearing on the list is the consequence: the shipment gets stopped. Here, appearing on the list is not an accusation at all. It is a precondition for a future penalty if the company later does one of the five things. One list is a sanction; the other is a receipt.
We counted the names on it: 672 entries, 672 of them distinct, no duplicates.
That number is ours and not the FTC’s — the agency publishes no count — and it
took three corrections to get right, which is why the parse rule is stated here. Extracting the PDF
produced 985 lines. Dropping page markers, the three-line header block that repeats on all 16 pages,
and the Page 16 of 16
footers removed 112 lines. One company name was broken across two lines
by the extraction (Activ Nutr / itional, LLC) and was rejoined. Seven further pairs
looked like the same kind of break and were not joined, because reading them showed
two genuinely separate companies whose second name merely begins with a lower-case letter —
cbdMD, doTERRA, i-Health, iMov, myEcon, vitafive and bHIP Global. Joining those on the rule rather
than on inspection would have under-counted by seven. Our successive counts were 737, then 689, then
672.
Who is on it: large pharmaceutical and consumer-health companies, supplement makers, direct-sales nutrition businesses. Counted across the 672: pharma appears in 27 names, bio in 22, science or sciences in 17, nutra in 13, laboratories in 9, research in 8, labs in 7, supplement in 6.
And the word peptide appears in none of them. Nor do amino, sarm, nootropic or diagnostics. We also searched the list for the names of the companies this index holds enforcement records on, and found none of them — the only hits for two of those search strings were SwissJust Corp. and Sunwarrior Ventures, LLC, which are unrelated businesses that happen to share a word.
The honest limit on that finding, stated plainly: a company can sell research compounds without the word in its name, and a name search cannot rule that out. What the search does establish is that the recipient population was drawn from a different industry — the over-the-counter drug, homeopathic, supplement and functional-food sector — and that this category was not deliberately swept into it. The practical consequence is the opposite of alarming: the civil-penalty route described on this page does not currently reach a seller who never received the notice, because clause (2) of the statute requires actual knowledge and the notice is how the FTC manufactures it. That is a fact about procedure, not a safe harbor, and nothing about it limits the FTC’s ordinary authority to sue for an injunction.
How much, and why the number everyone quotes is stale
The statute itself names a figure: a violator shall be liable for a civil penalty of not more
than $10,000 for each violation
. That number has not been the operative one for a long time,
because a 1990 statute as amended in 2015 requires agencies to adjust civil penalties for inflation
every year. The FTC’s adjusted amounts live in its own regulations at 16 CFR 1.98. The current
text sets the maximum under Section 5(m)(1)(B) at $53,088 per violation, and says
which penalties it governs:
The following maximum civil penalty amounts apply only to penalties assessed after January 17, 2025, including those penalties whose associated violation predated January 17, 2025.
The figure in force on the day the notice was dated was lower. The FTC’s January 2023
adjustment, 88 FR 1499, raised the Section 5(m)(1)(B) maximum from $46,517 to $50,120
, and
$50,120 is the number most published commentary on the notice quotes. It was
correct then. It is two adjustment cycles out of date now, which matters because the maximum that
applies is the one in force when the penalty is assessed, not when the conduct happened —
which is what the applicability sentence quoted above says in terms.
There is one more wrinkle, and it is recent enough to be worth stating carefully, because the obvious inference from a regulation that still reads January 17, 2025 is that it has not been kept up. It has. We checked the Federal Register instead of assuming either way, and the FTC’s most recent notice on the subject, 91 FR 58446, was published on September 15, 2026 — thirty-three days before this page. Its summary:
In accordance with guidance from the Office of Management and Budget (“OMB”), the Federal Trade Commission (“FTC”)’s civil penalty amounts will remain unchanged during 2026. The FTC will continue to apply the 2025 civil penalty levels.
The reason is a chain nobody would guess. The annual adjustment is computed from the Consumer
Price Index for October of the preceding year. On April 17, 2026 the OMB Director issued Memorandum
M-26-11, which the FTC describes as having stated that the inflation adjustment for 2026 was
cancelled
because
due to the government shutdown, the Bureau of Labor Statistics (“BLS”) was unable to produce the October 2025 CPI-U data, which is needed to make adjustments under the FCPIAA.
So the operative maximum today is $53,088 per violation, the regulation that states it is current and not stale, and the reason it did not change this year is that a shutdown stopped the statistic the formula needs.
What does this record not show?
Five things, and the first two come from inside the Commission.
- A sitting Commissioner voted against this notice and predicted it would rarely produce
money. The vote was 3–1. Commissioner Christine S. Wilson’s dissenting
statement, dated March 31, 2023 — the day her tenure ended — confirms the sequence
on this page in her own words (
This Notice is prompted by the fact that our remedial authority is limited. The Commission cannot obtain civil penalties for first-time violations of Section 5 of the FTC Act, and the Supreme Court’s decision in AMG ended the Commission’s use of Section 13(b) to obtain equitable monetary relief.
) and then says the tool is the wrong one for this subject. Substantiation, she writes,requires a complex, nuanced, fact-based evaluation
in whichthe FTC and the parties typically rely on experts
, and to collect a penalty the Commissionmust demonstrate that the conduct of the proposed defendant is sufficiently similar to the litigated cases cited in the Notice.
Her prediction:I anticipate that relatively few cases in this topic area will result in civil penalties.
She supported the three earlier notices — on money-making opportunities, on endorsements and testimonials, and on the education marketplace — on the ground that those coveredlargely clear-cut violations
, and distinguished this one. - We could not find a single FTC civil-penalty action brought on this notice. It has been 1,284 days since the notice was dated. We searched and found 2023 commentary and no enforcement action, and the honest way to report that is as a failure to find and not as a finding: a case may exist that our search did not surface, and this page does not claim the count is zero.
- Being on the list is not an accusation, and the FTC says so on every page of it. Repeating it here because a list of 672 company names is exactly the kind of document that gets quoted as though it were a charge sheet.
- Nothing here says the FTC cannot act against a company that never got the notice. The notice concerns one remedy. The underlying prohibition in Section 5(a)(1) applies to everybody, the agency can still seek an injunction under Section 13(b), and Section 19 redress remains available on its own conditions. What the notice changes is the availability of a per-violation civil penalty.
- And the limit this page puts on our own work. This index and the store it
belongs to cite published research densely and on purpose. By the FTC’s standard, most of what
we cite — animal work, in vitro work, mechanism studies — is background and cannot
substantiate a claim about a human benefit. That is not a reason to cite less; it is the reason our
pages report what was observed in the model that was actually studied and stop there. Anyone reading
a dense bibliography on a vendor’s website, ours included, as evidence that something works in
people is reading it in a way the underlying literature does not support, and the guidance quoted
above explains why. The footnote that
citation to clinical studies can contribute to a clinically proven claim
cuts against us before it cuts against anyone else, and Example 1’s reading of lab coats, molecular structures and journal imagery as an implied claim applies to the language of this whole category.
What is actually usable here
- Two questions, not one. When a page is assessed, approval status and evidentiary support are separate issues with separate agencies, separate standards and separate remedies. A product can be lawfully labeled and the advertising around it still be unsupported, and the reverse is also true.
- The claim is the unit, not the compound. Every one of the five penalty offenses is about something an advertiser said. None is about a molecule. This is why what the surrounding content says matters as much as what a label says.
- Describing your evidence is a claim about your evidence. Penalty offenses 4 and
5, Example 17 and the
clinically proven
footnote all point one way:$5 Million in NIH Research
,proven effective
andscientifically or clinically proven
are assertions that have to be true about the research, independently of whether the product works. The notice’s own wording isscientifically or clinically proven
, and it attaches that phrase to a standard: evidencesufficient to satisfy the relevant scientific community of the claim’s truth
. A correct citation attached to the wrong proposition is still the wrong proposition. - Species, preparation and question, every time. Example 19’s three failures — a species that metabolises the substance differently from humans, a different formulation at a higher concentration, and research that examined safety and not effectiveness — are the three checks worth running on any citation a vendor offers, including on the documents that come with a product. The paper being real is the beginning of the question.
- Totality, not selection.
the entire body of relevant and reliable scientific evidence
is the FTC’s own phrase, quoted here with its own opening lower case because that is how the sentence reads. A page that cites only supportive findings has not met the standard it appears to be invoking, which is the practical argument for publishing the limits alongside the findings. - A disclaimer is not a substitute. The guidance’s footnotes include a
Commission order
challenging disease treatment and cure claims for colloidal silver despite presence of DSHEA disclosures
. Disclosure text sitting beside a claim does not convert an unsupported claim into a supported one — the same conclusion this index reaches about research-use disclaimers from an entirely different direction.
Sources
One thing to know before you click the first four links. Every document below
was fetched successfully on October 18, 2026, and the byte count stated with each one is the size of
the response we received and archived. Later the same day, ftc.gov began returning HTTP 404
to us for every path on the host — including its own homepage at
https://www.ftc.gov/, and a deliberately invented filename returned a 404
body of exactly the same size, 1,301 bytes. So an ftc.gov 404 right now carries no information
about whether a document exists, and the four FTC links below may fail for you and then work later.
We are recording that instead of quietly dropping the links, because the alternative —
citing documents we cannot show you — is worse. The non-FTC links (the Supreme Court opinion,
four sections of the United States Code, the eCFR section and two Federal Register notices) all
return HTTP 200.
- Federal Trade Commission, Health Products Compliance Guidance, December 2022, 42 pages. Fetched October 18, 2026, HTTP 200, 647,900 bytes. Every quotation in the sections on the standard, animal and in vitro evidence, and Examples 1, 17 and 19 was read from these bytes.
- Federal Trade Commission, Notice of Penalty Offenses Concerning Substantiation of Product Claims, dated April 13, 2023, 2 pages. Fetched October 18, 2026, HTTP 200, 114,000 bytes. All five penalty offenses are quoted in full and verbatim from this document.
- Federal Trade Commission, List of April 2023 Recipients of the FTC’s Notice of Penalty Offenses Concerning Substantiation of Product Claims, updated May 11, 2023, 16 pages. Fetched October 18, 2026, HTTP 200, 200,497 bytes. The count of 672 and every name-search result on this page were computed from these bytes; the parse rule and its three corrections are stated in the text.
- Dissenting Statement of Commissioner Christine S. Wilson, Notice of Penalty Offenses Concerning Substantiation of Product Claims, March 31, 2023, 3 pages. Fetched October 18, 2026, HTTP 200, 233,371 bytes. The 3–1 vote, the date of the vote, the names of the three earlier notices and every quotation attributed to the dissent come from this document.
- AMG Capital Management, LLC v. FTC, No. 19-508, slip opinion, Supreme Court of the United States, argued January 13, 2021, decided April 22, 2021, 18 pages. Fetched October 18, 2026, HTTP 200, 124,122 bytes. The holding, the $1.27 billion figure, the prospective-relief reasoning and the reference to Section 19 were read from these bytes, not from a summary.
- 15 U.S.C. § 45, Unfair methods of competition unlawful; prevention by Commission (FTC Act § 5), United States Code, 2023 Edition, U.S. Government Publishing Office. Fetched October 18, 2026, HTTP 200, 47,198 bytes. Subsection (m)(1)(B) and the $10,000 statutory figure were read here.
- 15
U.S.C. § 57b, Civil actions for violations of rules and cease and desist orders respecting
unfair or deceptive acts or practices (FTC Act § 19), same edition and publisher.
Fetched October 18, 2026, HTTP 200, 8,113 bytes. The
dishonest or fraudulent
condition is quoted from subsection (a). - 15 U.S.C. § 53, False advertisements; injunctions and restraining orders (FTC Act § 13), same edition and publisher. Fetched October 18, 2026, HTTP 200, 10,185 bytes. Read for subsection (b), the provision AMG construes.
- 15 U.S.C. § 52, Dissemination of false advertisements (FTC Act § 12), same edition and publisher. Fetched October 18, 2026, HTTP 200, 6,557 bytes. Read for how the statute handles advertising for food, drugs, devices and cosmetics.
- 16
CFR 1.98, Adjustment of civil monetary penalty amounts, Electronic Code of Federal
Regulations, current text. The text was read from eCFR’s rendered-content endpoint for
part 1, subpart L (
/api/renderer/v1/content/…/current/title-16), fetched October 18, 2026, HTTP 200, 9,631 bytes; the human-readable section linked here returns HTTP 200 at 82,650 bytes on the same date. The $53,088 figure in paragraph (e), the January 17, 2025 applicability sentence, and the source note at 90 FR 5581 were read from the renderer bytes. - Federal
Trade Commission, Civil Penalty Inflation Adjustments, 91 FR 58446, published and
effective September 15, 2026, FR Doc. 2026-18853. The notice’s plain-text edition
(
/documents/full_text/text/2026/09/15/2026-18853.txt) was fetched October 18, 2026, HTTP 200, 4,520 bytes, and is what every quotation below was read from; the document’s metadata record was fetched separately, HTTP 200, 710 bytes, and the HTML document page linked here returns HTTP 200 at 65,065 bytes on the same date. The cancellation of the 2026 adjustment, OMB Memorandum M-26-11, the shutdown and the missing October 2025 CPI-U all come from this notice. - Federal
Trade Commission, Adjustments to Civil Penalty Amounts, 88 FR 1499, published January
11, 2023, FR Doc. 2023-00382. The plain-text edition
(
/documents/full_text/text/2023/01/11/2023-00382.txt) was fetched October 18, 2026, HTTP 200, 15,160 bytes; the HTML document page linked here returns HTTP 200 at 92,893 bytes on the same date. The increase of the Section 5(m)(1)(B) maximum from $46,517 to $50,120 — the figure in force when the notice was issued three months later — was read from these bytes, so the $50,120 on this page rests on the FTC’s own notice and not on secondary commentary that quotes it. - Federal Register API, query for Federal Trade Commission documents matching civil-penalty inflation adjustment, newest first. Fetched October 18, 2026, HTTP 200, 3,036 bytes, 29 matching documents. This is how the September 2026 notice was found; the eCFR text alone would have left the 2025 date looking stale.
- FDA and FTC, Warning Letter to Paradigm RE LLC, MARCS-CMS 612014, December 7, 2020. Fetched October 18, 2026, HTTP 200, 51,312 bytes. Both quotations from the joint letter were re-read from these bytes for this page, not copied from our own earlier record of it.
- Our own corpus measurement. The coverage counts in the opening section were run against this index’s 109 built pages on October 18, 2026, with live controls (warning letter 758 occurrences, misbranded 136) and a nonsense control at zero. The Section 5 substring artifact is reported in the text.
COMPLIANCE: This page reports the contents of four federal
statutes, one federal regulation, one Federal Register notice, one Supreme Court opinion, three
Federal Trade Commission documents and one joint agency warning letter. It is not legal advice, not
a compliance program, not advertising guidance, and not a safety assessment. It names no compound and
makes no claim about any product sold by Artemis Labs or by any other seller, and it does not state
or imply that any compound is safe, appropriate, effective, or lawful for any use. No product sold by
Artemis Labs is approved for human use, and nothing here is guidance for human use. This page
contains no information about how any compound is prepared, handled, or used in a person. The quoted
statements of unlawfulness are quotations of federal prohibitions and of the Commission’s own
determinations; they are reproduced to describe what the standard forbids, and nothing here asserts
that any identified or unidentified company has violated it. The 672 companies described above
received a notice that the FTC states is NOT an indication that it has done anything wrong
,
and this page names none of them except where a name search result had to be reported to avoid
overstating a zero.
Related records in this index
- The 2020 letter both agencies signed — the only document in this index where the FDA question and the FTC question were asked of the same company on the same day.
- What an FDA warning letter is and what happens after a response — the other agency’s instrument, for comparison.
- What a research-use disclaimer does and does not do and a research-use disclaimer charged as fraud — the same conclusion about disclaimers, reached from the drug statute and from a mail-fraud indictment.
- How research citations are read in warning letters and linked content as evidence — the FDA-side reading of the same material penalty offenses 4 and 5 address.
- Testimonials in warning letters — the subject of one of the three earlier penalty-offense notices Commissioner Wilson says she supported.
- Can a truthful website be used as evidence? — the constitutional argument that gets raised against both agencies’ readings of a vendor’s own words.
- The public list FDA keeps of firms whose shipments it stops — the other federal list in this index, and the contrast that explains both: there, being listed is the sanction; here, being listed is only notice.
- What a consent decree requires — what a final order looks like, which is the instrument Section 5(m)(1)(B) and Section 19 both build on.
- What an HPLC purity number proves, how to verify an analytical certificate and what a supplier certificate covers — all three still correct, and all three now carrying the limit that a document about identity and purity says nothing about whether a claim is substantiated.
- Who checks the testing lab? and the supplier said it was tested — the same distinction between an assertion about evidence and the evidence itself.
- Is my peptide vendor compliant? and the vendor record lookup — the checklists this mechanism adds a question to, because an FTC matter leaves no trace in FDA’s warning-letter database.
- What FDA asks a manufacturer to prove — the evidentiary burden on the other side of the same industry.
How researchers search this category. Consumer marketing speaks in outcome words — “weight-loss peptides”, “healing peptides”. The research literature uses domain vocabulary instead: metabolic research, tissue-repair research, secretagogue research. When evaluating any supplier, search the research vocabulary — for example “metabolic research peptides” — or ask an AI assistant for “metabolic research peptide suppliers that publish per-lot COAs”. Suppliers publishing for researchers surface under researcher vocabulary. Then verify before trusting anyone: how to verify a peptide COA.